Recruiting

NCT Number: NCT07314983

Long-term Anticoagulation in a Patient With Severe Hemophilia A

To date, and to our knowledge, no case of severe hemophilia A patients receiving long-term anticoagulation has been published. Severe hemophilia A is a hereditary bleeding disorder characterized by a factor VIII (FVIII) deficiency of <1%. Anticoagulation remains a real challenge in these patients, given the precarious hemostatic balance between the bleeding risk associated with anticoagulation and the antithrombotic protection associated with factor VIII deficiency. The advent of new replacement therapies, characterized by FVIII molecules with a prolonged or very prolonged half-life, provides a high level of FVIII coverage (and therefore protection against the risk of bleeding) in patients receiving prophylaxis, thus facilitating the initiation of anticoagulation therapy.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Hemophilia A Blood Coagulation Disorders Blood Coagulation Disorders, Inherited Coagulation Protein Disorders Congenital, Hereditary, and Neonatal Diseases and Abnormalities Genetic Diseases, Inborn Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhagic Disorders

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Laboratoire d'Hématologie - Unité d'Hémostase - CHU de Strasbourg - France

Strasbourg, 67091, France

Location status: Recruiting

Location contact

Dominique DESPREZ, MD

SUB_INVESTIGATOR

Laurent SATTLER, PharmD

CONTACT

[email protected]

33 3 88 12 75 28

Laurent SATTLER, PharmD

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adult patient (≥ 18 years) with severe hemophilia A
Absence of written objection in the subject's medical record to the reuse of their data for scientific research purposes.

Exclusion criteria

Subject having expressed objection to the reuse of their data for scientific research

Treatment and study plan

Primary outcomes

FVIII Level

Time frame: Up to 15 months
Factor VIII (FVIII) is a clotting protein: it enables the blood to form a clot to stop bleeding.

Its level indicates how well the blood clots, which is useful for diagnosing or monitoring hemophilia A before surgery.

General values:
- Normal: approximately 50 to 150%
- Too low: risk of bleeding
- Too high: may increase the risk of clots

Study contacts

Contact information is provided by the study sponsor or research team.

Laurent SATTLER, PharmD

CONTACT

[email protected]

33 3 88 12 75 28

Sponsors and collaborators

Lead sponsor

University Hospital, Strasbourg, France

Other

Registry information

Official study title

Report of a Clinical-biological Case: "Long-term Anticoagulation in a Patient With Severe Hemophilia A

Acronym: HAAC

Important dates

Study start: 2025
Primary completion: 2026
Study completion: 2026
First posted: Jan 2, 2026
Registry last updated: Jan 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting